BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 05, 2015
 |  BioCentury  |  Finance

Lighting up neoantigens

How Third Rock start-up Neon plans to tap neoantigen biology for cancer

Investors led by Third Rock Ventures put $55 million into Neon Therapeutics Inc. to exploit recently discovered neoantigen biology from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute. Neon will develop both personalized and allogeneic therapeutic vaccines and T cell therapies for cancer that preclinical models suggest could be as effective as checkpoint inhibition.

According to Third Rock partner and Neon interim CEO Cary Pfeffer, neoantigens result from mutations that occur during tumor growth and are recognized by the immune system as foreign. He said the potential importance...

Read the full 447 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >